Recent Advances in Large-Cell Lymphomas
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 282
Special Issue Editor
Interests: large cell lymphomas; multiple myeloma; lymphoproliferative disorders
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Lymphoma is one of the most common malignant tumors, with an increasing number of cases year by year. Lymphomas are classified into more than 100 subtypes in the current WHO classification. This year, the WHO established criteria for the classification of hematolymphoid tumors based on recent advances in the clinicopathological and genomic/genetic findings. At the same time, the Clinical Advisory Committee also published the International Consensus Classification (ICC). These two classifications are similar in view of the progress to date, but there are several differences in the nomenclature of types and definitions of disease subtypes. In the future, these two classifications will be utilized in parallel, recognizing their differences and the developing hematopathology.
This Special Issue focuses on recent advances in lymphomas, particularly those composed of large cells, irrespective of lineage. We seek expert review articles as well as research articles on recent advances in large-cell lymphomas.
Prof. Dr. Shuji Momose
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lymphoma
- large cell lymphoma
- hematolymphoid tumor
- hematopathology
- clinicopathological research
- genomic research
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
